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Abstract
Expression of several cytokines involved in signal transduction such as TGF-1 and the inflammatory chemokines including MCP-1 is
elevated during the course of AIDS progression. The enhancement of these cellular proteins in astrocytic cells is mediated, at least in part,
by HIV-1 Tat protein. Here, we investigate the possible regulation of MCP-1 transcription by Tat and the Smad family of transcription
factors whose activities are induced by the TGF-1 pathway. Results from transfection studies revealed that Smad-3 stimulates basal and
Tat-mediated transcription of MCP-1 in human astrocytic cells. Smad-4, on the other hand, had no effect on the basal activity of the MCP-1
promoter, but showed the ability to decrease both Smad-3 and Tat-induced transcription of the MCP promoter. Results from protein-binding
studies revealed the ability of both Smad-3 and Smad-4 to associate with the region of Tat spanning residues 1–40. Examination of the
transcriptional activity of the various domains of Smad including MH1, at the N-terminus, and MH2, at the C-terminus of the protein
indicated that neither MH1 or MH2 alone positively cooperate with Tat in modulating MCP-1 transcription. However, ectopic expression
of MH1 and, more notably, MH2 severely suppressed transcriptional activation of MCP-1 by Tat in astrocytic cells. Binding studies revealed
that similar to the full-length Smad protein, both MH1 and MH2 associate with Tat protein and that the residues between 1 and 40 of Tat
are important for their interaction. These observations reveal a novel mechanism for Tat-mediated transcriptional activation via TGF
signaling pathway and provide evidence for regulation of MCP-1 gene transcription by this signaling pathway in human astrocytic cells.
© 2003 Elsevier Science (USA). All rights reserved.
A variety of direct and indirect stimuli such as viral
infection, trauma, and autoimmune disorders can result in
the activation and directed migration of leukocytes into the
area of tissue injury. One of the major complications of
HIV-1 infection is the syndrome of cognitive and motor
dysfunction, so-called HIV-1-associated dementia (HAD)
(Lipton and Gendelman, 1995). The neuropathology asso-
ciated with HAD, termed encephalitis, is characterized by
infiltration of immune cells, particularly monocytic cells
such as macrophages and microglia, by myelin pallor, and
by reactive astrocytosis (Budka et al., 1987; Nielson et al.,
1994; Sharer and Kapila, 1985). While the mechanism re-
sponsible for monocytic infiltration of the brain remains
elusive, there have been several reports suggesting that
enhanced expression of several cytokines and chemokines
by the infected monocytic cells as well as astrocytes may be
involved in the recruitment of the inflammatory cells. For
example, enhancement in the level of transforming growth
factor, TGF, a cytokine with a potent chemotactic activity
for monocytes, has been observed in HIV-1-infected mono-
cytic macrophages both in cell culture and in brain tissue of
AIDS patients (Wahl et al., 1987, 1991). Accordingly, our
results show that HIV-1 regulatory protein, Tat, enhances
the promoter activity of TGF in human astrocytic cells
(Cupp et al., 1993; Rasty et al., 1996; Sawaya et al., 1998).
On the other hand, several reports link HIV-1 infection of
macrophages to an increased level of several monocyte
chemoattractant chemokines such as Rantes, MIP1, and
MIP1 (Canque et al., 1996; Mengozzi et al., 1999;
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Schmidtmayerova et al., 1996). Furthermore, induction of
the chemoattractant protein 1 (MCP-1), one of the most
potent monocyte chemoattractants which are commonly in-
duced in astrocytes, has been reported during the course of
AIDS dementia (Conant et al., 1998). Similar to TGF, the
elevation of MCP-1 expression in astrocytes seems to be
mediated by the Tat protein (Conant et al., 1998; Lim and
Garzino-Demo, 2000).
Tat is a small early viral protein whose expression is
essential for the transcription of the HIV-1 genome in the
infected cells. To exert its activity, Tat interacts with the
TAR RNA sequence located in the leader of the viral tran-
script where it associates with several cellular proteins
which are involved in the process of transcription initiation
and elongation (Herrmann and Rice, 1995). In addition,
several reports have established the ability of Tat to stimu-
late transcription of TAR-negative cellular genes including
TNF, TGF, MCP-1, and IL-1 through alternative mech-
anisms that involve its association with several DNA-bind-
ing proteins (Conant et al., 1998; Cupp et al., 1993; Glass et
al., 1993; Nottet et al., 1995; Sawaya et al., 1998; Zauli et
al., 1992). The ability of Tat to stimulate expression of
TGF, a protein that can stimulate a signaling pathway
involving the Smad family of transcription factors (Wotton
and Massague, 2001), prompted us to investigate transcrip-
tion of the MCP-1 promoter activity in astrocytes.
In the first series of experiments, we assessed the ability
of two important downstream substrates of the TGF sig-
naling pathway, i.e., Smad-3 and Smad-4, in regulating
transcription of MCP-1 in human astrocytic cells. Results
from cotransfection studies revealed that ectopic expression
of Smad-3, but not Smad-4, drastically elevates the MCP-1
promoter encompassing the region between 500 and 1
(Fig. 1). Of interest, Smad-4 showed an inhibitory effect on
Smad-3-mediated activation of MCP-1 transcription. Pro-
gressive removal of the nucleotide sequences between
500 and 100 decreased (more than 50%) the extent of
MCP-1 activation by Smad-3, yet maintained the inhibitory
effect of Smad-4 on Smad-3. It was also noted that Smad-
4 exhibited a less inhibitory effect than Smad-3 on the
activation of the MCP-1 promoter containing 100 to 1
in the transfected cells. Altogether, these observations sug-
gested that TGF signaling factors such as Smad-3 can
up-regulate transcription of the MCP-1 promoter and that
Fig. 1. Regulation of the MCP-1 promoter by Smad-3 and Smad-4. A series of DNA fragments corresponding to the MCP-1 promoter region spanning
nucleotides 500 to 1, 400 to 1, 300 to 1, 200 to 1, and 100 to 1 were created by gene amplification using specific DNA primers. The
amplified DNAs were placed at the 5 region of the CAT reporter gene and after verification by direct sequencing, each reporter construct was used in the
transfection assay. In the transfection study, the human astrocytic glial cell line, U-87MG (ATCC), was maintained in Dulbecco’s minimal essential medium
containing 10% fetal calf serum (Gibco-BRL, Rockville, MD) and supplemented with antibiotics (100 units/ml penicillin, 50 g/ml streptomycin-G). Cells
(5  105) cultured on 60-mm plates and grown overnight were transfected by the calcium phosphate precipitation method as described by Gallia et al. (1999)
with 5.0 g of the reporter DNA either alone or together with 5.0 g of a plasmid expressing Smad-3 and Smad-4. The amount of DNA used for transfection
was normalized with pCDNA-3 plasmid. Cell extracts were prepared 48 h after transfection and CAT assay was performed. The bar graphs demonstrate an
average fold effect of Smad-3, Smad-4, and Smad-3 plus Smad-4 on the basal MCP-1 promoter activity from three independent experiments.
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the intracellular concentration of Smad-3 and Smad-4 can
dictate the extent of MCP-1 transcription in astrocytic cells.
In the next series of experiments, we evaluated the co-
operative action of Smad-3 and Smad-4 with HIV-1 Tat on
transcription of the MCP-1 promoter. As shown in Fig. 2,
coproduction of Smad-3 and Tat caused a synergistic acti-
vation of the MCP-1 promoter. Again, the observed activa-
tion of MCP-1 by Smad-3 and Tat, either alone or together,
was drastically decreased in cells overexpressing Smad-4
(Fig. 2A). Similar results were obtained when the MCP-1
minimal promoter sequence (100/1) was tested in the
transfection assay.
As Tat exerts its activity through association with other
cellular proteins, we evaluated the possible association of
Tat with Smad-3. Results from GST pull-down experiments
using protein extracts from U-87MG that overexpressed
Smad-3 revealed binding of the Smad-3 to GST-Tat, but not
GST (Fig. 3A). To further investigate the specificity of
Tat:Smad-3 interaction and determine the region within Tat
that can participate in this event, we created a series of
deletion mutant Tat proteins in fusion with GST and utilized
them in the GST pull- down assay. As illustrated in Fig. 3B,
removal of the region between residues 1 and 40 completely
abrogated Tat interaction with Smad-3. It was also noted
that the mutant peptide containing only the residues be-
tween 1 and 50 has a reduced binding activity to Smad-3
compared to the smaller deletions spanning the amino acids
between 1 and 40. This observation implies that the residues
between 40 and 50 of Tat may modulate its interaction with
Smad-3. A similar approach was adapted to study the asso-
ciation of Tat with Smad-4. Results from GST pull-down
assay demonstrated that Tat also associates with Smad-4
(Fig 3C) and that the use of Tat deletion mutants of the
N-terminus region of Tat indicated that the region spanning
residues 1 to 40 is essential for this interaction (Fig. 3D).
Interestingly, unlike its interaction with Smad-3, mutant 1 to
50 showed a binding affinity to Smad-4 comparable to that
of mutant 1 to 40. As summarized in Fig. 3E, these data
show that both Smad-3 and Smad-4 physically associate
with Tat and the residues of Tat between 1 and 40 are
critical for their interaction.
The Smad family of transcription factors contains com-
mon features and is composed of two major domains MH1
and MH2, which are separated by a linker domain (for
review, see Wotton and Massague, 2001). As illustrated
in Fig. 4A, the MH1 domain of Smad-3 is known for its
DNA-binding activity, while MH2 appears to function as
the activation domain of Smad-3 and interacts with other
DNA-binding proteins.
To gain more information regarding the mechanism for
Tat and Smad regulation of the MCP-1 promoter, we cre-
ated expression plasmids that permit production of two
distinct domains of Smad, i.e., MH1 and MH2. Toward this
end, PCR-amplified DNA fragments corresponding to MH1
and MH2 were fused to myc Tag DNA fragment and the
pCDNA-3 expression plasmid. Production of MH1 and
MH2 in U-87MG cells was verified by Western blot anal-
ysis using anti-Myc-specific antibody (Fig. 4B). Function-
ally, expression of the MH1 domain caused a modest in-
duction of the MCP-1 promoter (Fig. 4C). MH2 showed a
minimal, if any, stimulatory effect on MCP-1 transcription.
Coexpression of MH1 and Tat slightly decreased the ability
of Tat to enhance MCP-1 transcription. Under similar con-
ditions, MH2 expression either alone or with MH1 caused a
drastic negative effect on the ability of Tat to stimulate
MCP-1 transcription. Coproduction of Smad-3 with either
MH1 or MH2 alone or together in the cells, abrogated the
ability of Smad-3 to stimulate MCP-1 transcription. These
observations demonstrate that MH2, and to some extent,
MH1 domains of Smad-3 negatively affect the level of
activation of the MCP-1 promoter by Tat. Furthermore, both
Fig. 2. Effect of Smad-3 and Smad-4 on Tat-induced transcription of the
MCP-1 promoter. U-87MG cells were transfected with 5 g of reporter
constructs containing 500 to 1 (top) or 100 to 1 (bottom) of the
MCP-1 promoter along with 5 g of Tat expression plasmid, 5 g of
Smad-3 expression plasmid, and 5 g of Smad-4 expression plasmid in
various combinations as shown. Fold effect demonstrates the average of
three independent experiments.
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MH1 and MH2 domains can function as dominant-negative
proteins and diminish the level of MCP-1 transcription by
Smad-3 in astrocytic cells.
In the next study, we evaluated binding activity of MH1
and MH2 domains to Tat protein. Results shown in Fig. 5
indicate that, similar to full-length Smad-3 protein, MH1
has the ability to associate with Tat and that removal of the
region between 40 and 72 decreases, but does not abolish,
its binding activity. The Tat mutant protein containing res-
idues 40 to 72 failed to associate with MH1, suggesting that
the critical region for MH1 and Tat interaction resides
between residues 1 and 40 of Tat. Examination of MH2
interaction with Tat by GST pull-down assay showed a very
weak and comparable association of MH2 with the various
mutants of Tat, although it was noted that mutant 40 to 72
exhibited a slightly weaker binding activity to MH2 than the
other Tat mutants.
In sum, the data presented in this article suggest a po-
tential mechanism for activation of the MCP-1 promoter by
HIV-1 Tat through the regulatory proteins that respond to
Fig. 3. Interaction of Smad-3 and Smad-4 with Tat protein. Protein extracts from U-87MG cells transfected with plasmids expressing either Smad-3 (A and
B) or Smad-4 (C and D) were prepared and utilized in GST pull-down assay according to the procedure described earlier (Gallia et al., 1999). (A) illustrates
results from binding of Smad-3 to GST or GST-Tat (1–86) and (B) demonstrates results from binding of Smad-3 to GST and the various mutants of Tat as
indicated (Massague, 1998; Sawaya et al., 2000). Lanes 1 in (A) and (B) illustrate the presence of Smad-3 in a 1/10 volume of extract (30 g) that was used
in each GST pull-down assay. (C) and (D) demonstrate binding of GST and GST-Tat (1–86) and Tat mutants to Smad-4. (E) highlights the level of binding
of Smad-3 and Smad-4 to the Tat mutant peptides.  (strong),  (weak), / (very weak), and  (none). (F) illustrates Coomassie blue staining of 10%
SDS–PAGE depicting quality of the various Tat proteins that were used in GST pull-down assay.
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the TGF signaling pathway. This is an interesting obser-
vation in light of previous data showing that HIV-1 Tat has
the ability to stimulate TGF gene expression in astrocytic
cells (Cupp et al., 1993; Rasty et al., 1996; Sawaya et al.,
1998). Thus, one may speculate that Tat activation of TGF
in astrocytes induces downstream regulators of TGF sig-
naling molecules such as Smads that, alone or in coopera-
tion with Tat, modulate expression of MCP-1. In earlier
studies it was shown that Tat can also induce expression of
tumor necrosis factor- (TNF) in various cells and during
the course of viral infection of T cells (Buonaguro et al.,
1992; Chen et al., 1997; Sawaya et al., 1998). With the
notion that both TNF and TGF elevate expression of
several chemokines in astrocytic cells (Hurwitz et al., 1995;
Oh et al., 1999), one may postulate that the stimulatory
effect of Tat on expression of chemokines including MCP-1
can be indirect and involve signaling pathways such as
TNF and TGF (New et al., 1997; Sawaya et al., 1998). In
support of this notion, earlier studies indicated that binding
of the NF-B transcription factors, whose activity is in-
duced in response to TNF, to the MCP promoter DNA
sequence is increased upon Tat treatment of human astro-
cytic cells (Lim and Garzino-Demo, 2000).
Our data add Smads to the list of cellular proteins that
physically and functionally interact with Tat. Earlier studies
on the mechanism of Tat activation of the HIV-1 promoter
showed that interaction of Tat with TAR RNA of the LTR
on one hand, and cyclin T and cdk9 on the other hand,
results in the positioning of cyclin T and cdk9 in close
proximity to the transcription start site where they phos-
phorylate carboxyl terminal domain of RNA polymerase II
(Richter et al., 2002; Zhou and Rana, 2002). Other studies
have revealed that association of Tat with several other
cellular proteins with DNA-binding activity enables Tat to
stimulate transcription of genes with no TAR sequence
(Ansari et al., 1999; Darbinian et al., 2001; Gallia et al.,
1999; Jeang et al., 1993; Taylor et al., 1994). For example,
the association of Tat with Pur can result in the activation
of the JC virus and TGF promoters in glial cells (Krach-
marov et al., 1996; Thatikunta et al., 1997). Similarly, the
Fig. 4. Effect of MH1 and MH2 on the ability of Tat and Smad-3 in up-regulating the MCP-1 promoter. (A) Schematic representation of Smad-3 structure
demonstrating MH1, linker, and MH2 domains. (B) Expression of MH1 and MH2 by the plasmid containing the myc Tag DNA sequence fused to the DNA
corresponding to the sequence expressing MH1 and MH2 was determined by Western blot analysis. Human astrocytic U-87MG cells were transfected with
15 g of a plasmid encoding pCMV-Myc-MH1 and/or MH2. Forty-eight hours posttransfection, cell extracts (50 g samples) derived from the transfected
cells were subjected to Western blot analysis using a Myc-antibody which recognizes the Myc portion in pCMV-Myc-MH1 or MH2 (Santa Cruz
Biotechnology, Santa Cruz, CA). The bands corresponding to MH1 and MH2 fusion proteins are shown. (C) U-87MG cells were transfected with 5 g of
MCP-1 reporter constructs (500 to 1) alone or together with plasmids expressing Tat (5 g), Smad-3 (5 g), MH1, and MH2 domains (5 g). All
expression plasmids have the same background vector (pcDNA3) and their genes are transcribed by the CMV promoter. The amount of plasmid DNA in each
transfection was normalized by empty vector DNA. The values on top of each bar graph represent the average of two separate experiments.
200 Rapid Communication / Virology 309 (2003) 196–202
interaction of Tat with the NF-B subunits or SP1 under
certain physiologic conditions enables Tat to stimulate
TAR-negative HIV-1 LTR transcription (Taylor et al.,
1994; Widlak et al., 1997). The cooperative interaction of
Tat with Smad-3 upon the MCP-1 promoter indicates that
under these conditions, when the TGF signaling pathway
is at work, expression of MCP-1 gene in astrocytes can be
affected by Smads. Further, our results reveal new peptides,
MH1 and MH2 that can be utilized as inhibitory compounds
to block activation of MCP-1 by Tat. Currently, studies are
in progress to assess the ability of MH1 and MH2 in sup-
pressing MCP-1 expression in response to TGF stimulation
in several other cell types as well as in an in vitro system.
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